Critical Path Should Follow GMP Model, FDA’s Woodcock Says
This article was originally published in The Pink Sheet Daily
Executive Summary
To avoid public pushback, the Critical Path initiative should focus on science, not regulatory overhauls, Woodcock tells DIA.
You may also be interested in...
Biomarker Consortium To Launch In October
The public/private partnership is administered by NIH and includes FDA, CMS, patient efficacy groups and industry.
Biomarker Consortium To Launch In October
The public/private partnership is administered by NIH and includes FDA, CMS, patient efficacy groups and industry.
FDA Aims To Regulate Clinical Trial Third-Party Investigators
The agency is working on a proposed rule that would require companies to report data falsification by sub-investigators, according to deputy commissioner Woodcock.